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Background: Standardized questionnaires designed for the identification of depression are useful for monitoring
individual as well as population mental health. The Edinburgh Postnatal Depression Scale (EPDS) has originally been
developed to assist primary care health professionals to detect postnatal depression, but several authors recommend
its use outside of the postpartum period. In Brazil, the use of the EPDS for screening depression outside the postpartum
period and among non-selected populations has not been validated. The present study aimed to assess the validity of
the EPDS as a screening instrument for major depressive episode (MDE) among adults from the general population.
Methods: This is a validation study that used a population-based sampling technique to select the participants. The
study was conducted in the city of Pelotas, Brazil. Households were randomly selected by two stage conglomerates with
probability proportional to size. EPDS was administered to 447 adults (≥20 years). Approximately 17 days later, participants
were reinterviewed by psychiatrics and psychologists using a structured diagnostic interview (Mini International
Neuropsychiatric Interview, MINI). We calculated the sensitivity and specificity of each cutoff point of EPDS, and values
were plotted as a receiver operator characteristic curve.
Results: The best cutoff point for screening depression was ≥8, with 80.0% (64.4 - 90.9%) sensitivity and 87.0%
(83.3 - 90.1%) specificity. Among women the best cutoff point was ≥8 too with values of sensitivity and specificity
of 84.4% (67.2 – 94.7%) and 81.3% (75.5 – 86.1%), respectively. Among men, the best cutoff point was ≥7
(75% sensitivity and 89% specificity).
Conclusions: The EPDS was shown to be suitable for screening MDE among adults in the community.
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Depression is one of the most prevalent mental health
disorders all around the world. It interferes with inter-
personal relationships and affects the performance of
everyday activities [1]. Depression is responsible for a
considerable amount of health expenditure, with high
economic impact at the level of households, firms and
governments [2]. The latest Global Burden of Disease
study showed that major depressive disorder was the* Correspondence: tyagomunhoz@hotmail.com
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article, unless otherwise stated.second leading cause of years lived with disability
(YLDs) and a major contributor to the burden of suicide
and ischemic heart disease worldwide [3].
A study that included eighteen countries and considered
a recall period of one year reported the highest major de-
pressive episode (MDE) prevalence in United States,
Ukraine and Brazil (8.3%, 8.4% and 10.4%, respectively) [4].
However, the rates of depression in Brazil are variable, due
to the adopted instrument to detect MDE, time frame
coverage and different sampling methodology. A recent
systematic review and meta-analysis of population-based
studies reported a prevalence of depressive symptoms ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and a lifetime prevalence of major depressive disorder of
17% among Brazilian adults [5].
Individuals that experience depression are more likely
to have new episodes of depression throughout life and
comorbidity with other mental health disorders such as
anxiety, social phobia and other chronic diseases [6-8],
situation that is exacerbated in the absence of adequate
treatment. Failure to correctly identify depression can
not only negatively impact the health of the individuals,
but also could result in an inadequate provision of men-
tal health services in the community [9]. In addition to be
affected by prejudice and stigmatization, families bear a
significant proportion of the economic and social burden
of the disease, due to the lack or inefficiency of available
mental health services, a situation most frequent among
developing countries [10-12].
Standardized questionnaires designed for the identifi-
cation of depression are useful for monitoring individual
as well as population mental health. Characteristics of
the instruments such as the number of questions, easy
of understanding, good psychometric properties and free
access increase their potential applicability both in re-
search and clinical settings. A great deal of questionnaires
are currently available to assess depression, however, many
are time consuming, complex and designed to be per-
formed by interviewers highly trained in mental health.
The most frequent instruments used for screening depres-
sion in Brazil are the Beck Depression Inventory (BDI),
the “Geriatric Depression Scale” (GDS) and the Patient
Health Questionnaire-9 (PHQ-9). Each instrument has
been validated in the Brazilian population and has advan-
tages and limitations that have been reported in previous
studies [13-15].
The Edinburgh Postnatal Depression Scale (EPDS), a
10-item scale, developed by Cox et al. was originally de-
vised for the identification of postpartum depression dis-
orders [16]. The use of EPDS is favoured because of the
ease and speed of its administration. The clinical and
epidemiological value of the scale has been confirmed by
several validation studies carried out in different coun-
tries mostly among women in the postpartum period,
with both sensitivity and specificity in the 70-85% range,
depending on the cutoff point [17-25]. Although the
EPDS was developed for screening depression in women
postnatally, it has been shown to be useful in the assess-
ment of women outside the postnatal period and has
been validated among men [21,22]. The fact that the
EPDS is already known by health professionals due to its
use in the perinatal and postpartum period raises the
question whether this instrument could be applied to
the adult population outside of the postnatal period. In
Brazil, the use of the EPDS for screening depression out-
side the postpartum period and among non-selectedpopulations has not been validated. Thus, the present
study aimed to assess the validity of the EPDS as a
screening instrument for MDE among adults from the
general population.
Methods
A population-based cross-sectional study was conducted
in the urban area of Pelotas, state of Rio Grande do Sul,
southern Brazil, between February and June 2012, to as-
sess the health of adolescents, adults and elderly residents.
The city of Pelotas has 328,275 inhabitants according to
the 2010 Census and its population is predominantly
urban (93.3%). A sampling design of two-stage conglomer-
ates with probability proportional to size was used. Ac-
cording to the 2010 Population Census there were 495
census tracts, the primary sampling units. The secondary
sampling units were households. All private households
with permanent resident as of December 2011 in the 130
census tracts selected were listed. They were then randomly
selected by applying probability proportional to size. All
residents of selected households with 20 or more years of
age were eligible for the study. Individuals who had cogni-
tive or mental disabilities confirmed by the fieldwork super-
visor as well as those institutionalized (hospitals, elderly
homes, among others) were excluded. Participants were
interviewed at home by trained interviewers through the
application of a structured questionnaire. Information was
obtained on demographic, environmental and socioeco-
nomic variables and work and health-related behaviours.
Instrument
The EPDS was originally devised for the identification of
postpartum depression disorders for use in clinical and re-
search settings. EPDS is a self-administered, 10-item scale;
each item has four possible responses from 0 to 3, with a
minimum score of 0 and a maximum of 30. The scale ex-
presses the intensity of depressive symptoms over the pre-
ceding seven days. All participants completed the EPDS
questionnaire. We used a Brazilian version of the question-
naire. Questions were translated into Portuguese, back-
translated again into English and tested in a previous study
[24]. In contrast to the original self-administered format,
questions were posed to individuals by a trained interviewer,
as a single block and in the same order as in the original in-
strument. The decision to pose the questions verbally was
due to the fact that an important proportion of participants
had little schooling as well as being unfamiliar with self-
administered data collection instruments. The administra-
tion of EPDS as an interview is accepted by the instrument's
authors [16] and has been previously used [17,24].
Sample for the validation study
The validation study was conducted only among adults
(≥20 years). The sample was selected weekly from
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households included in the main study was randomly se-
lected to be included in the validation study sample. The
person responsible for selecting the participants was not
aware of EPDS results applied in the main study. More
than one adult per household was eligible to be included
in the validation study. The present validation study was
designed to detect sensitivity and specificity ≥80%, with
an error of ten percentage points and a significance level
at 95%. The acceptable error was compatible with the lo-
gistics of the study and considered satisfactory for a val-
idation study. According to these parameters it would be
necessary to include around 200 individuals with MDE
and 200 normal.Gold standard instrument
The Mini International Neuropsychiatric Interview
(MINI), validated in a Brazilian population [26], was
chosen as the gold standard instrument. The MINI was
designed to be used both in clinical practice and in epi-
demiological studies and evaluates the presence of men-
tal disorders according to the Diagnostic and Statistical
Manual of Mental Disorders – IV revision (DSM-IV)
and the International Statistical Classification of Dis-
eases and Related Health Problems – 10th Revision
(ICD-10). It was tested against the Structured Clinical
Interview for Diagnosis (SCID) and found to be reliable
and valid. For depressive disorders, the MINI showed a
sensitivity and specificity of 92%, Kappa 0.77, positive
predictive value (PPV) 74%, negative predictive value
(NPV) 98% and accuracy of 92% [26].
Adults selected to be included in the validation study
sample were invited to receive a home visit from a mental
health professional (psychiatry, psychologist or psychiatric
resident), all previously trained in the application and in-
terpretation of the gold standard instrument. Training was
carried out through seminars and role plays of the MINI
application, with the consultant clarifying questions in
each session (total duration of 30 h).
The presence of MDE was considered as a gold standard
diagnostic. All individuals considered positive for MDE
answered an additional group of questions regarding other
possible causes for the symptoms, such as direct effects of
substances, the presence of organic disorder or other med-
ical illness, the presence of psychotic symptoms or if the
symptoms would be better explained by reaction to be-
reavement, and in this case MDE diagnosis was discarded.
Mental health professionals were blinded to participants’
EPDS scores.
Interviews with mental health professionals (gold
standard) were performed on average 24 days after the
application of the EPDS (minimum interval of 0 days,
maximum of 93 days and median of 17 days).Data analysis
For each EPDS cutoff point, we calculated the sensitivity
or true positive rate (proportion of individuals with
MDE according to MINI criteria that were correctly
identified by EPDS), specificity or true negative rate
(proportion of individuals without MDE according to the
gold standard correctly identified as such by EPDS), PPV
(proportion of true positives among all positives identified
by the EPDS) and NPV (proportion of true negatives
among all those who scored negative by EPDS). We calcu-
lated 95% confidence intervals for each of these parameters.
We used Youden’s index as a criterion for choosing
the “optimal” threshold value for the EPDS test, the
threshold value for which the value of [sensitivity + spe-
cificity −1] is maximized.
Criterion validity was assessed by receiver operating
characteristic (ROC) curves. The ROC curve is a plot of
the sensitivity versus [1-specificity] over all possible
threshold values of the test being validated. The EPDS
point showing simultaneously the highest sensitivity and
specificity was also evaluated using the ROC curve.
EPDS’s accuracy (proportion of results, both positive and
negative, correctly identified by the EPDS) was estimated
by the area under the ROC curve.
In order to identify how the EPDS would perform
among populations with different depression prevalence
rates we performed simulations with different prevalence
rates and calculated the PPV based on the sensitivity
and specificity obtained for the EPDS at the cutoff points
most commonly used internationally [27].
Analyses were conducted for the entire sample and
separately for men and women. All analyses were per-
formed using Stata® version 12.0 sofware.
Ethical approval for both the main research and the
validation study was granted by the Research Ethics
Committee of the Federal University of Pelotas School
of Medicine (protocols 77/2011 and 14/2012, respect-
ively). All respondents signed a consent form prior to
data collection. Individuals who were at risk of suicide
or had severe symptoms of depression were home visited
by mental health providers and/or were referred to men-
tal health care services.
Results
Of 533 individuals selected for the gold standard inter-
view, we had a participation rate of 84% (n = 447). There
were 29 refusals, 51 individuals couldn’t be found at home
after at least three attempts and six moved out of the city.
Socio-demographic characteristics of the sample are
presented in Table 1. A total of 191 men and 256 (57.3%)
women were included in the study. Regarding socio-
demographic variables, 54.8% had 9 or more years of
schooling, 42.3% were 40–59 years old, 76.5% self-
reported their skin colour as White, 34.5% were single or
Table 1 Characteristics of the sample included in the
validation of the Edinburgh Postnatal Depression Scale
(n = 477) and losses (n = 86), Pelotas, 2012
Variables Sample Losses p-valuea
n (%) n (%)
Female 256 (57.3) 47 (54.6) 0.65
Schooling (years) 0.27
0-4 68 (15.3) 9 (10.6)
5-8 133 (29.9) 32 (37.6)
≥ 9 244 (54.8) 44 (51.8)
Age (years) 0.14
20-39 183 (40.9) 44 (51.2)
40-59 189 (42.3) 33 (38.3)
≥ 60 75 (16.8) 9 (10.5)
White skin colour 342 (76.5) 70 (81.4) 0.32
Single/without partner 154 (34.5) 34 (39.5) 0.36
Working status 0.52
Working 263 (58.8) 52 (60.5)
Not currently working 164 (36.7) 28 (32.6)
Never worked 20 (4.5) 6 (7.0)
Smoking 105 (23.5) 23 (26.7) 0.51
Alcohol use 187 (41.8) 37 (43.0) 0.83
ax2 test.
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employed. Concerning behavioural variables 23.5% were
smokers and 41.8% reported alcohol consumption in the
month preceding the interview. Individuals lost to the gold
standard interview were similar to those who were inter-
viewed in all investigated characteristics (Table 1).
EPDS and MINI scale reliability calculated using Cron-
bach's alpha was 0.8366 and 0.7875, respectively. Cron-
bach's alpha range calculated by omitting each question
of the instrument ranged between 0.8011-0.8460 for
EPDS and 0.7429-0.7910 for MINI.
The gold standard interview identified 40 individuals
with MDE (32 women and eight men), corresponding to
a global prevalence of MDE of 8.9% (CI 95% 6.3 – 11.6).
Table 2 shows sensitivity, specificity, PPV, NPV and ac-
curacy for each of the EPDS cutoff points compared to
the gold standard interview. As expected, sensitivity de-
creased progressively as the cutoff point increased, with
a more marked decrease between the ≥4 and ≥5 cutoff
points (from 90.0% to 82.5%). In contrast, specificity be-
tween these two cutoff points increased from 60.7% to
71.3%. Both Youden’s index and the cutoff point of max-
imum sensitivity and specificity according to the ROC
curve (Figure 1) indicate the ≥8 cutoff point as the most
suitable for identifying individuals at increased risk of
having MDE among this population. A total of 85 indi-
viduals (19.0%; 15.5 – 23.0%) scored ≥8 in the EPDS.Sensitivity at this point was 80.0% (64.4 – 90.9%) and
specificity of 87.0% (83.3 – 90.1%). The PPV and NPV
were 37.6% (27.4 – 48.8%) and 97.8% (95.7 – 99.0%), re-
spectively. The positive likelihood ratio at this point was
6.1 (4.6 – 8.3) and the area under the ROC curve indi-
cates an accuracy of the EPDS of 88.6%.
EPDS performance among women was very similar to
the results of the entire population (Figure 2). The best
cutoff point was ≥8 too with values of sensitivity and spe-
cificity of 84.4% (67.2 – 94.7%) and 81.3% (75.5 – 86.1%),
respectively. The PPV and NPV were 39.1% (27.6 – 51.6%)
and 97.3 (93.9 – 99.1%), respectively. The positive likeli-
hood ratio at this cutoff point was 4.5 (3.3 – 6.1) and the
area under the curve indicates an accuracy of the EPDS of
87.6%.
Among men, the best cutoff point according Youlden’s
index and the ROC curve (Figure 3) was ≥7. Sensitivity
at this point was 75.0% (34.9 – 96.8%) and specificity of
89.1% (83.6 – 93.2%). The PPV and NPV were 23.1%
(9.0 – 43.6%) and 98.8% (95.7 – 99.9%), respectively.
The positive likelihood ratio at this cutoff point was 6.9
(3.9 – 12.2) and the area under the ROC curve indicates
an accuracy of the EPDS of 87.7%.
The effect of changes in the prevalence of MDE in the
study population was observed in the PPV of EPDS.
Table 3 shows the PPV for EPDS cutoff points between
7 and 13 in simulations for populations with different
depression prevalence rates. Thus, for instance, if EPDS
was administered as a screening test with a cutoff point
of ≥8 in a population with a depression prevalence rate
of about 10%, the PPV would be 40.6%. In this case, 60%
of individuals identified by EPDS as suffering from de-
pression would actually be false-positives. If the preva-
lence rate of depression in the population increases, the
PPV increases as well, however, there still persist a large
number of false positives in the population. False posi-
tives would be less than 40% using a cutoff of ≥13 in a
population with a prevalence rate of depression of 10%
and false positive would be less than 25% with a preva-
lence rate of depression of 20%.
Discussion
The present study showed that the EPDS is a suitable test
for screening MDE among adults from the community
and living in an urban middle-sized city like Pelotas. A
screening test should focus on the sensitivity, in order to
maximize the number of individuals who could be in need
of health care. Using the cutoff point of ≥8 and with a
prevalence of MDE in the population of about 10%,
around 20% of individuals will be EPDS positive and when
referred to mental health services, half will be diagnosed
with MDE. To be used as a diagnostic test, the EPDS cut-
off point needs to be higher, with a suggested cutoff point
of ≥13, favouring the specificity instead of the sensitivity.
Table 2 Number of positive individuals (%) according to the Edinburgh Postnatal Depression Scale (EPDS), sensitivity,
specificity, PPV, NPV, accuracy ( 95% confidence intervals) for different EPDS cutoff points compared to the gold
standard (International Neuropsychiatric Interview) and Youden’s index, adult population from Pelotas (n = 447), 2012
Cutoff points N (%) Sensitivity
(CI 95%) %
Specificity (CI 95%) % PPV % NPV % Accuracy % Youden’s
index (*)
≥ 1 363 (81.2) 100.0 (91.2 – 100.0) 20.6 (16.8 – 24.9) 11.0 (8.0 – 14.7) 100.0 (95.7 – 100.0) 60.3 (58.4 – 62.3) 0.206
≥ 2 303 (67.8) 97.5 (86.8 – 99.9) 35.1 (30.5 – 40.0) 12.9 (9.3 – 17.2) 99.3 (96.2 – 100.0) 66.3 (62.9 – 70.0) 0.326
≥ 3 239 (53.5) 95.0 (83.1 – 99.4) 50.6 (45.6 – 55.6) 15.9 (11.5 – 21.2) 99.0 (96.6 – 99.9) 72.8 (68.6 – 77.0) 0.456
≥ 4 196 (43.8) 90.0 (76.3 – 97.2) 60.7 (55.8 – 65.5) 18.4 (13.2 – 24.5) 98.4 (96.0 – 99.6) 75.3 (70.1 – 80.6) 0.507
≥ 5 150 (33.6) 82.5 (67.2 – 92.7) 71.3 (66.6 – 75.6) 22.0 (15.7 – 29.5) 97.6 (95.2 – 99.0) 76.9 (70.5 – 83.2) 0.538
≥ 6 122 (27.3) 82.5 (67.2 – 92.7) 78.1 (73.8 – 82.1) 27.0 (19.4 – 35.8) 97.8 (95.6 – 99.1) 80.3 (74.0 – 86.6) 0.606
≥ 7 102 (22.8) 82.5 (67.2 – 92.7) 83.0 (79.0 – 86.6) 32.4 (23.4 – 42.3) 98.0 (95.9 – 99.2) 82.8 (76.5 – 89.0) 0.655
≥ 8 85 (19.0) 80.0 (64.4 – 90.9) 87.0 (83.3 – 90.1) 37.6 (27.4 – 48.8) 97.8 (95.7 – 99.0) 83.5 (77.0 – 90.0) 0.670
≥ 9 67 (15.0) 72.5 (56.1 – 85.4) 90.7 (87.4 – 93.3) 43.3 (31.2 – 56.0) 97.1 (94.9 – 98.5) 81.6 (74.4 – 88.7) 0.632
≥10 61 (13.6) 70.0 (53.5 – 83.4) 91.9 (88.8 – 94.4) 45.9 (33.1 – 59.2) 96.9 (94.6 – 98.4) 80.9 (73.6 – 88.3) 0.619
≥ 11 53 (11.9) 65.0 (48.3 – 79.4) 93.4 (90.5 – 95.6) 49.1 (35.1 – 63.2) 96.4 (94.1 – 98.0) 79.2 (71.6 – 86.8) 0.584
≥ 12 43 (9.6) 55.0 (38.5 – 70.7) 94.8 (92.2 – 96.8) 51.2 (35.5 – 66.7) 99.5 (93.0 – 97.3) 74.9 (67.0 – 82.8) 0.498
≥ 13 33 (7.4) 47.5 (31.5 – 63.9) 96.6 (94.3 – 98.1) 57.6 (39.2 – 74.5) 94.9 (92.4 – 96.8) 72.0 (64.1 – 79.9) 0.441
≥ 14 29 (6.5) 45.0 (29.3 – 61.5) 97.3 (95.2 – 98.6) 62.1 (42.3 – 79.3) 94.7 (92.1 – 96.7) 71.1 (63.3 – 79.0) 0.423
≥ 15 23 (5.1) 35.0 (20.6 – 51.7) 97.8 (95.8 – 99.0) 60.9 (38.5 – 80.3) 93.9 (91.1 – 96.0) 66.4 (58.9 – 73.9) 0.328
≥ 16 18 (4.0) 25.0 (12.7 – 41.2) 98.0 (96.2 – 99.1) 55.6 (30.8 – 78.5) 93.0 (90.2 – 95.2) 61.5 (54.7 – 68.3) 0.230
≥ 17 15 (3.4) 22.5 (10.8 – 38.5) 98.5 (96.8 – 99.5) 60.0 (32.3 – 83.7) 92.8 (90.0 – 95.1) 60.5 (53.9 – 67.1) 0.210
≥ 18 12 (2.7) 20.0 (9.1 – 35.6) 99.0 (97.5 – 99.7) 66.7 (34.9 – 90.1) 92.6 (89.8 – 94.9) 59.5 (53.2 – 65.8) 0.190
≥ 19 10 (2.2) 17.5 (7.3 – 32.8) 99.3 (97.9 – 99.8) 70.0 (34.8 – 93.3) 92.4 (89.6 – 94.7) 58.4 (52.4 – 64.4) 0.168
≥ 20 10 (2.2) 17.5 (7.3 – 32.8) 99.3 (97.9 – 99.8) 70.0 (34.8 – 93.3) 92.4 (89.6 – 94.7) 58.4 (52.4 – 64.4) 0.168
≥ 21 7 (1.6) 12.5 (4.2 – 26.8) 99.5 (98.2 – 99.9) 71.4 (29.0 – 96.3) 92.0 (89.1 – 94.4) 56.0 (50.8 – 61.2) 0.120
≥ 22 6 (1.3) 12.5 (4.2 – 26.8) 99.8 (98.6 – 100) 83.3 (35.9 – 99.6) 92.1 (89.1 – 94.4) 56.1 (50.9 – 61.3) 0.123
≥ 23 4 (0.9) 10.0 (2.8 – 23.7) 100.0 (99.1 – 100.0) 100.0 (39.8 – 100.0) 91.9 (88.9 – 94.2) 55.0 (50.3 – 59.7) 0.100
Note: PPV = positive predictive value; NPV = negative predictive value.














Area under ROC curve = 0,8863
Figure 1 Receiver operator characteristic curve for the
performance of the Edinburgh Postnatal Depression Scale
compared to an interview with a mental health Professional using
Mini International Neuropsychiatric Interview (gold standard) for
the diagnosis of major depressive episode. Pelotas, 2012 (n=447).
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http://www.biomedcentral.com/1471-244X/14/284The EPDS was originally devised for the identification of
postpartum depression disorders for use in clinical and re-
search settings [16]. The clinical and epidemiological value
of the scale has been confirmed by several validation studies
carried out among women in the antenatal and postpartum
period all around the world [19,22,23,25,28-30]. In Brazil,
the EPDS was previously validated among women showing
good psychometric properties [17,18,24,31]. However, in
the only population-based validation study carried out in
the postpartum period made in Brazil, sensitivity, specificity
and PPVs for all cutoff points were below those previously
reported, especially when compared to studies from high-
income countries [24]. The EPDS was also validated among
men in the postpartum period [21,32,33], having been
found more accurate than the Beck Depression Inventory
(BDI) and the Patient Health Questionnaire – Depression













Area under ROC curve = 0,8755
Figure 2 Receiver operator characteristic curve for the
performance of the Edinburgh Postnatal Depression Scale
compared to an interview with a mental health Professional using
Mini International Neuropsychiatric Interview (gold standard) for
the diagnosis of major depressive episode among women.
Pelotas, 2012 (n=256).
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the scale can be referred to as Edinburgh Depression
Scale (EDS) [34], few validation studies were identified
[34-36]. Cox et al. [34] validated the EPDS among 136
women recruited from general practice registers that
were non-pregnant and who had had no births in the
previous year. The authors reported an acceptable EPDS
performance for screening major depression with a cut-
off point of 12/13 (sensitivity, specificity and PPV of
88%, 80% and 21%, respectively) using Goldberg’s Clin-
ical Interview Schedule as the gold standard. The EPDS
was also validated in a large community sample of 951
menopausal women by Becht et al. [35] using the Re-













Area under ROC curve = 0,8767
Figure 3 Receiver operator characteristic curve for the
performance of the Edinburgh Postnatal Depression Scale
compared to an interview with a mental health Professional
using Mini International Neuropsychiatric Interview (gold
standard) for the diagnosis of major depressive episode
among men. Pelotas, 2012 (n=191).EPDS was chosen to be applied in this population of
women because it doesn’t include somatic symptoms re-
lated to menopause, such as sleeping problems and sex-
ual dysfunction. With a cutoff point of 12 points or
higher, the EPDS showed appropriate psychometric
characteristics for screening major depressive disorder
(sensitivity, specificity and PPV of 88%, 85% and 40%, re-
spectively). The advantage of the EPDS of not containing
any somatic-type symptom was also considered by
Lloyd-Williams et al. [36] in their study of 100 patients
(55 females and 44 males) with advanced metastatic can-
cer receiving palliative care and using the Present State
Examination (semi structured psychiatric interview) as
gold standard. With a cutoff of 13 or higher, the EPDS
showed similar sensitivity and PPV to the study per-
formed among women at menopausal age (sensitivity,
specificity and PPV of 81%, 79% and 53%, respectively).
In our study with a cutoff score of ≥8, the percentage
of correctly identified people with MDE was similar to
those of the three other validation studies performed
outside the postpartum period (all sensitivities fell within
the 95% confidence interval of our estimative) [34-36].
The PPV values of our study for different cutoff points
were not very high, but still almost two-times higher
than the values observed in Cox et al. study [34], prob-
ably due to the small sample size of their study.
The best cutoff point for screening depression in our
study (≥8) was lower than the cutoff point recommended
for screening MDE among those studies performed out-
side the postpartum period [34-36]. In addition, for a 12/
13 cutoff, EPDS sensitivity dropped to less than 50% and
its specificity almost reach 95%, values that could be found
in a diagnostic test and not suitable for screening. The
EPDS cutoff scores vary from culture-to-culture and rec-
ommendations have been made to validate the instrument
before applying it for screening to a population [37].
In our study, the EPDS score values were more concen-
trated among men and very few of them (only eight) were
diagnosed as depressed by our gold standard. Better EPDS
performance among women than among men was seen in
a previous study performed in the postpartum period [38].
Our literature review identified very few validation studies
of the EPDS among people from the general population
outside the prenatal or postpartum period. In addition,
difficulties have been reported to reach the necessary
number of men in the study to calculate EPDS’s psycho-
metric properties in this group [39].
Our study was the first EPDS validation study for
screening MDE among people from the general popula-
tion and outside the postpartum period in Brazil. The
EPDS has a long track record of being routinely adminis-
tered not only to mothers but also fathers in the postnatal
period. Given the ease of administration and acceptability
as well as its good psychometric properties the EPDS
Table 3 Positive predictive values (confidence intervals of
95%) for different Edinburgh Postnatal Depression Scale
(EPDS) cutoff points, according to the prevalence of
depression in the study population, Pelotas, 2012
Cutoff point Positive predictive value
EPDS ≥7
Prevalence of depression
5% 20.4 (16.5 – 24.9)
10% 35.1 (29.5 – 41.2)
15% 46.2 (39.9 – 52.6)
20% 54.9 (48.4 – 61.2)
25% 61.9 (55.6 – 67.7)
EPDS ≥8
Prevalence of depression
5% 24.4 (19.4 – 30.3)
10% 40.6 (33.7 – 47.8)
15% 52.0 (44.7 – 59.3)
20% 60.6 (53.3 – 67.4)
25% 67.2 (60.4 – 73.3)
EPDS ≥9
Prevalence of depression
5% 29.0 (22.2 – 36.9)
10% 46.3 (37.6 – 55.2)
15% 57.8 (48.9 – 66.2)
20% 66.0 (57.6 – 73.5)
25% 72.1 (64.4 – 78.7)
EPDS ≥10
Prevalence of depression
5% 31.2 (23.6 – 40.0)
10% 49.0 (39.5 – 58.5)
15% 60.4 (50.9 – 69.1)
20% 68.3 (59.5 – 76.0)
25% 74.2 (66.2 – 80.9)
EPDS ≥11
Prevalence of depression
5% 34.0 (25.1 – 44.2)
10% 52.1 (41.5 – 62.6)
15% 63.4 (52.9 – 72.7)
20% 71.0 (61.5 – 79.0)
25% 76.6 (68.0 – 83.4)
EPDS ≥12
Prevalence of depression
5% 35.9 (25.3 – 48.1)
10% 54.2 (41.8 – 66.2)
15% 65.3 (53.2 – 75.7)
20% 72.7 (61.7 – 81.5)
25% 78.0 (68.3 – 85.4)
Table 3 Positive predictive values (confidence intervals of
95%) for different Edinburgh Postnatal Depression Scale
(EPDS) cutoff points, according to the prevalence of




5% 42.1 (28.3 – 57.2)
10% 60.5 (45.5 – 73.8)
15% 70.9 (57.0 – 81.8)
20% 77.5 (65.2 – 86.4)
25% 82.2 (71.5 – 89.4)
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population in both research and clinical settings. Adminis-
tration of the scale as an interview was appropriate for the
cultural characteristics of people included in the sample.
However, it is possible that this strategy could have biased
the respondents’ answers due to social desirability effect of
face-to-face interview and our results could not be gener-
alized to situations where the EPDS is self-reported.
Among other limitations of the study, we had 16% of indi-
viduals that could not undergo the gold standard interview
and, though, were not included in the validation sample.
They were similar to those included in the sample regard-
ing all socioeconomic, demographic and behavioural char-
acteristics investigated. In addition, the prevalence of
EPDS ≥8 among people that failed to be included in the
validation sample was similar to those included in the
sample (24% versus 19%, respectively, p = 0.250). It looks
like the loss of these individuals may not have impaired
the sensitivity estimation in the present study. Another
limitation was the gap of about 17 days (median) between
the EPDS and the gold standard administration. It is pos-
sible that depressive symptoms may have changed over
this period, mainly because the test was designed to en-
quire about feelings over the last seven days. However, it is
frequently observed that depressive symptoms usually per-
sist for weeks or even months [40]. Finally, care should be
taken when deciding to compare the results of previously
EPDS validation studies with our study. Methodological is-
sues such as the prevalence of depression in the target
population, how cases were defined by the instrument
chosen as gold standard, the design of the study and the
specific characteristic of the population where the valid-
ation was performed, are all characteristics that could
affect the EPDS’s psychometric properties.
Conclusions
In conclusion, the EPDS was shown to be suitable for
screening MDE among adult populations living in the
urban area of medium-sized cities and with similar cul-
tural characteristics to the population where the present
Matijasevich et al. BMC Psychiatry 2014, 14:284 Page 8 of 9
http://www.biomedcentral.com/1471-244X/14/284study was conducted. The EPDS can easily be applied
by trained interviewers, not necessarily psychiatrics or
psychologists which are in short supply in low and
middle-income countries, and this continues to be the
main advantage of the instrument. Even though the
final diagnostic of depression can only be confirmed
through an interview with a mental health professional,
the EPDS could be used to monitor MDE prevalence in
the community. More studies are needed in men,
where EPDS psychometric properties of the test could
not be tested properly.
Abbreviations
EPDS: Edinburgh postnatal depression scale; MDE: Major depressive episode;
MINI: Mini international neuropsychiatric interview; DSM-IV: Diagnostic and
statistical manual of mental disorders – IV revision; ICD-10: International
statistical classification of diseases and related health problems – 10th
revision; ROC: Receiver operator characteristic; PHQ-9: Patient health
questionnaire; EDS: Edinburgh depression scale; PPV: Positive predictive
value; NPV: Negative predictive value.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
AM participated in the design of the study, undertook the analysis,
interpreted the results and drafted the first version of the article. IS Santos
designed the study and collaborated with the interpretation of the findings
and writing of the article. TNM, BFT, APPNB, DMS, MSA, TAD contributed to
the interpretation of the findings and the writing of the article. All authors
approved the final version of the manuscript submitted.
Acknowledgments
We are extremely grateful to all the participants for their contributions to this
research. I. S. Santos and A. Matijasevich receive research support from the
National Council for Scientific and Technological Development (CNPq), Brazil.
Author details
1Departament of Preventive Medicine, School of Medicine, University of São
Paulo, São Paulo, Brazil. 2Postgraduate Program in Epidemiology, Federal
University of Pelotas, Pelotas, Brazil. 3Department of Mental Health, Faculty of
Medicine, Federal University of Pelotas, Pelotas, Brazil. 4Catholic University of
Pelotas, Pelotas, Brazil. 5Centro de Pesquisas Epidemiológicas - Universidade
Federal de Pelotas, Rua Marechal Deodoro, 1160, Pelotas, RS CEP: 96020-220 -
Caixa Postal 464, Brasil.
Received: 6 June 2014 Accepted: 30 September 2014
References
1. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, Ustun TB,
Wang PS: The global burden of mental disorders: an update from the
WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009,
18:23–33.
2. Goetzel RZ, Pei X, Tabrizi MJ, Henke RM, Kowlessar N, Nelson CF, Metz RD:
Ten modifiable health risk factors are linked to more than one-fifth of
employer-employee health care spending. Health Aff (Millwood) 2012,
31:2474–2484.
3. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T,
Whiteford HA: Burden of depressive disorders by country, sex, age, and
year: findings from the global burden of disease study 2010. PLoS Med
2013, 10:e1001547.
4. Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA,
Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam
AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y,
Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ: Age differences in
the prevalence and co-morbidity of DSM-IV major depressive episodes:results from the WHO World Mental Health Survey Initiative.
Depress Anxiety 2010, 27:351–364.
5. Silva MT, Galvao TF, Martins SS, Pereira MG: Prevalence of depression
morbidity among Brazilian adults: a systematic review and
meta-analysis. Rev Bras Psiquiatr 2014, 36:262–270.
6. Boing AF, Melo GR, Boing AC, Moretti-Pires RO, Peres KG, Peres MA:
Association between depression and chronic diseases: results from a
population-based study. Rev Saude Publica 2012, 46:617–623.
7. Gabilondo A, Vilagut G, Pinto-Meza A, Haro JM, Alonso J: Comorbidity of
major depressive episode and chronic physical conditions in Spain, a
country with low prevalence of depression. Gen Hosp Psychiatry 2012,
34:510–517.
8. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B: Depression,
chronic diseases, and decrements in health: results from the World
Health Surveys. Lancet 2007, 370:851–858.
9. Meyer C: Depressive disorders were the fourth leading cause of global
disease burden in the year 2000. Evid Based Ment Health 2004, 7:123.
10. Alonso J, Buron A, Bruffaerts R, He Y, Posada-Villa J, Lepine JP, Angermeyer
MC, Levinson D, de Girolamo G, Tachimori H, Mneimneh ZN, Medina-Mora
ME, Ormel J, Scott KM, Gureje O, Haro JM, Gluzman S, Lee S, Vilagut G,
Kessler RC, Von Korff M, World Mental Health C: Association of perceived
stigma and mood and anxiety disorders: results from the World Mental
Health Surveys. Acta Psychiatr Scand 2008, 118:305–314.
11. Sartorius N: Stigma and mental health. Lancet 2007, 370:810–811.
12. Schulze B: Mental-health stigma: expanding the focus, joining forces.
Lancet 2009, 373:362–363.
13. Wang YP, Gorenstein C: Psychometric properties of the Beck Depression
Inventory-II: a comprehensive review. Rev Bras Psiquiatr 2013, 35:416–431.
14. Castelo MS, Coelho-Filho JM, Carvalho AF, Lima JW, Noleto JC, Ribeiro KG,
Siqueira-Neto JI: Validity of the Brazilian version of the Geriatric Depres-
sion Scale (GDS) among primary care patients. Int Psychogeriatr 2010,
22:109–113.
15. Santos IS, Tavares BF, Munhoz TN, Almeida LS, Silva NT, Tams BD, Patella AM,
Matijasevich A: Sensitivity and specificity of the Patient Health
Questionnaire-9 (PHQ-9) among adults from the general population.
Cad Saude Publica 2013, 29:1533–1543.
16. Cox JL, Holden JM, Sagovsky R: Detection of postnatal depression.
Development of the 10-item Edinburgh Postnatal Depression Scale. Br J
Psychiatry 1987, 150:782–786.
17. da Silva VA, Moraes-Santos AR, Carvalho MS, Martins MLP, Texeira NA:
Prenatal and postnatal depression among low-income Brazilian women.
Braz J Med Biol Res 1998, 31:799–804.
18. Figueira P, Correa H, Malloy-Diniz L, Romano-Silva MA: Edinburgh Postnatal
Depression Scale for screening in the public health system. Rev Saude
Publica 2009, 43(Suppl 1):79–84.
19. Garcia-Esteve L, Ascaso C, Ojuel J, Navarro P: Validation of the Edinburgh
Postnatal Depression Scale (EPDS) in Spanish mothers. J Affect Disord
2003, 75:71–76.
20. Gibson J, McKenzie-McHarg K, Shakespeare J, Price J, Gray R: A systematic
review of studies validating the Edinburgh Postnatal Depression Scale in
antepartum and postpartum women. Acta Psychiatr Scand 2009,
119:350–364.
21. Matthey S, Barnett B, Kavanagh DJ, Howie P: Validation of the Edinburgh
Postnatal Depression Scale for men, and comparison of item
endorsement with their partners. J Affect Disord 2001, 64:175–184.
22. Murray L, Carothers AD: The validation of the Edinburgh Post-natal
Depression Scale on a community sample. Br J Psychiatry 1990, 157:288–290.
23. Pitanupong J, Liabsuetrakul T, Vittayanont A: Validation of the Thai
Edinburgh Postnatal Depression Scale for screening postpartum
depression. Psychiatry Res 2007, 149:253–259.
24. Santos IS, Matijasevich A, Tavares BF, Barros AJ, Botelho IP, Lapolli C,
Magalhaes PV, Barbosa AP, Barros FC: Validation of the Edinburgh
Postnatal Depression Scale (EPDS) in a sample of mothers from the 2004
Pelotas Birth Cohort Study. Cad Saude Publica 2007, 23:2577–2588.
25. Vivilaki VG, Dafermos V, Kogevinas M, Bitsios P, Lionis C: The Edinburgh
Postnatal Depression Scale: translation and validation for a Greek
sample. BMC Public Health 2009, 9:329.
26. de Azevedo Marques JM, Zuardi AW: Validity and applicability of the Mini
International Neuropsychiatric Interview administered by family
medicine residents in primary health care in Brazil. Gen Hosp Psychiatry
2008, 30:303–310.
Matijasevich et al. BMC Psychiatry 2014, 14:284 Page 9 of 9
http://www.biomedcentral.com/1471-244X/14/28427. Eberhard-Gran M, Eskild A, Tambs K, Opjordsmoen S, Samuelsen SO: Review
of validation studies of the Edinburgh Postnatal Depression Scale.
Acta Psychiatr Scand 2001, 104:243–249.
28. Benvenuti P, Ferrara M, Niccolai C, Valoriani V, Cox JL: The Edinburgh
Postnatal Depression Scale: validation for an Italian sample. J Affect
Disord 1999, 53:137–141.
29. Berle JO, Aarre TF, Mykletun A, Dahl AA, Holsten F: Screening for postnatal
depression. Validation of the Norwegian version of the Edinburgh
Postnatal Depression Scale, and assessment of risk factors for postnatal
depression. J Affect Disord 2003, 76:151–156.
30. Aydin N, Inandi T, Yigit A, Hodoglugil NN: Validation of the Turkish version
of the Edinburgh Postnatal Depression Scale among women within their
first postpartum year. Soc Psychiatry Psychiatr Epidemiol 2004, 39:483–486.
31. Santos MFS, Martins FC, Pasquali L: Escala de auto-avaliação de depressão
pós-parto: estudo no Brasil. Revista de Psiquiatria Clínica 1999, 26:90–95.
32. Edmondson OJ, Psychogiou L, Vlachos H, Netsi E, Ramchandani PG:
Depression in fathers in the postnatal period: assessment of the
Edinburgh Postnatal Depression Scale as a screening measure. J Affect
Disord 2010, 125:365–368.
33. Lai BP, Tang AK, Lee DT, Yip AS, Chung TK: Detecting postnatal depression
in Chinese men: a comparison of three instruments. Psychiatry Res 2010,
180:80–85.
34. Cox JL, Chapman G, Murray D, Jones P: Validation of the Edinburgh
Postnatal Depression Scale (EPDS) in non-postnatal women. J Affect
Disord 1996, 39:185–189.
35. Becht MC, Van Erp CF, Teeuwisse TM, Van Heck GL, Van Son MJ, Pop VJ:
Measuring depression in women around menopausal age: towards a
validation of the Edinburgh Depression Scale. J Affect Disord 2001,
63:209–213.
36. Lloyd-Williams M, Friedman T, Rudd N: Criterion validation of the
Edinburgh postnatal depression scale as a screening tool for depression
in patients with advanced metastatic cancer. J Pain Symptom Manage
2000, 20:259–265.
37. Halbreich U, Karkun S: Cross-cultural and social diversity of prevalence of
postpartum depression and depressive symptoms. J Affect Disord 2006,
91:97–111.
38. Areias ME, Kumar R, Barros H, Figueiredo E: Comparative incidence of
depression in women and men, during pregnancy and after childbirth.
Validation of the Edinburgh Postnatal Depression Scale in Portuguese
mothers. Br J Psychiatry 1996, 169:30–35.
39. Thorpe K: A study of the use of the Edinburgh Postnatal Depression
Scale wity parent groups outside the postpartum period. J Reprod Infant
Psychol 1993, 11:119–125.
40. Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA: Duration of
major depressive episodes in the general population: results from The
Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J
Psychiatry 2002, 181:208–213.
doi:10.1186/s12888-014-0284-x
Cite this article as: Matijasevich et al.: Validation of the Edinburgh
postnatal depression scale (EPDS) for screening of major depressive episode
among adults from the general population. BMC Psychiatry 2014 14:284.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
